Consultation open on revised EMA Guideline on Medicines to treat Alzheimer’s Disease
The European Medicines Agency (EMA) has released a draft guideline revision on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias for a six-month public consultation. The EMA considers dementia a key public health priority and sees early stage intervention and prevention of symptomatic disease as particularly worthy goals. This
Consultation open on revised EMA Guideline on Medicines to treat Alzheimer’s Disease Read More »